Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Lycanbull Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825866616254480384.png) Lycanbull [@Lycanbull](/creator/twitter/Lycanbull) on x 5175 followers
Created: 2025-07-21 10:59:19 UTC

$BMY Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally


![](https://pbs.twimg.com/card_img/1945800532867596289/tWjDCExI?format=png&name=600x314)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947250029359505866/c:line.svg)

**Related Topics**
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/Lycanbull/status/1947250029359505866)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Lycanbull Avatar Lycanbull @Lycanbull on x 5175 followers Created: 2025-07-21 10:59:19 UTC

$BMY Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

XXX engagements

Engagements Line Chart

Related Topics $bmy stocks healthcare

Post Link

post/tweet::1947250029359505866
/post/tweet::1947250029359505866